Glenza 160mg Tablet

About

Glenza 160mg Tablet contains Enzalutamide, an androgen receptor inhibitor that acts at multiple steps in the androgen receptor signaling pathway, inhibiting androgen binding, nuclear translocation, and DNA binding. This action prevents the growth and survival of prostate cancer cells that rely on androgen signaling, even in castration-resistant settings. It is used in the treatment of metastatic castration-resistant prostate cancer (mCRPC) and non-metastatic castration-resistant prostate cancer (nmCRPC), significantly improving progression-free survival and overall survival in these patient populations. Enzalutamide offers a crucial therapeutic option for men whose prostate cancer has progressed despite conventional hormone therapy, providing a targeted approach to disease management.

Uses

• Metastatic Castration-Resistant Prostate Cancer (mCRPC).
• Non-metastatic Castration-Resistant Prostate Cancer (nmCRPC).
• Metastatic Hormone-Sensitive Prostate Cancer (mHSPC).
• High-risk non-metastatic Castration-Sensitive Prostate Cancer (nmCSPC).

Directions For Use

Take orally once daily, with or without food. Swallow the tablet whole.

Benefits

• Extends overall survival in mCRPC.
• Delays disease progression.
• Improves quality of life for patients.
• Oral administration for convenience.
• Effective in both metastatic and non-metastatic settings.
• Offers a targeted approach to prostate cancer.

Side Effects

• Fatigue
• Asthenia
• Hot flashes
• Headache
• Hypertension
• Diarrhea
• Nausea
• Decreased appetite
• Falls
• Seizures (rare)
• Peripheral edema
• Musculoskeletal pain

Safety Measures

• Alcohol - No specific interaction, but excessive alcohol can exacerbate fatigue and other side effects.
• Pregnancy - Not for use in women. Potential for fetal harm if absorbed by pregnant women.
• Breastfeeding - Not for use in women.
• Liver - Use with caution in patients with severe hepatic impairment; dose adjustment may be necessary.
• Kidney - Use with caution in patients with severe renal impairment; no dose adjustment typically needed for mild-moderate.
• Lung - No specific lung-related safety notes commonly associated with enzalutamide.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.